Solid Biosciences (SLDB) Equity Average (2018 - 2026)

Solid Biosciences has disclosed Equity Average across 9 years of filings, most recently posting $277.1 million for Q1 2026.

• Equity Average for Q1 2026 came in at $277.1 million, up 28.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $277.1 million (up 28.36% YoY), and the FY2025 annual result was $158.6 million, up 20.3% from the prior year.
• Equity Average came in at $277.1 million for Q1 2026 at Solid Biosciences, up from $199.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $277.1 million in Q1 2026 to a low of $135.4 million in Q4 2023.
• The 5-year median for Equity Average is $180.1 million (2024), against an average of $192.4 million.
• Across the five-year window, Equity Average sank 33.77% in 2022 and jumped 36.83% in 2025, its largest moves.
• Solid Biosciences' Equity Average stood at $177.5 million in 2022, then decreased by 23.69% to $135.4 million in 2023, then grew by 12.34% to $152.1 million in 2024, then surged by 30.79% to $199.0 million in 2025, then jumped by 39.25% to $277.1 million in 2026.
• The last three Equity Average figures came in at $277.1 million (Q1 2026), $199.0 million (Q4 2025), and $238.1 million (Q3 2025), per Business Quant data.